



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GIGAVCOXP

(Page 1 of 2)

DOCTOR'S ORDERS		Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form				
DATE:	To be given:	Cycle(s) #:		
Date of Previous Cycle: _____				
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff day of treatment				
May proceed with doses as written if within 96 hours ANC greater than or equal to 1.2 x 10⁹/L, platelets greater than or equal to 75 x 10⁹/L, creatinine clearance greater than or equal to 50 mL/minute, creatinine less than or equal to 1.5 times the upper limit of normal and less than or equal to 1.5 times the baseline, ALT less than or equal to 3 times the upper limit of normal, total bilirubin less than or equal to 1.5 times the upper limit of normal				
Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity _____				
Proceed with treatment based on blood work from _____				
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.				
ondansetron 8 mg PO prior to treatment				
dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg (select one) PO prior to treatment (omit if below dexamethasone IV premedication ordered)				
For prior pembrolizumab infusion reaction:				
<input type="checkbox"/> diphenhydrAMINE 50 mg PO 30 minutes prior to pembrolizumab				
<input type="checkbox"/> acetaminophen 325 to 975 mg PO 30 minutes prior to pembrolizumab				
<input type="checkbox"/> hydrocortisone 25 mg IV 30 minutes prior to pembrolizumab				
<input type="checkbox"/> For prior oxaliplatin hypersensitivity reactions (Grade 1 or 2):				
45 minutes prior to oxaliplatin: dexamethasone 20 mg IV in 50 mL NS over 15 minutes				
30 minutes prior to oxaliplatin: diphenhydrAMINE 50 mg IV in NS 50 mL over 15 minutes and famotidine 20 mg IV in NS 100 mL over 15 minutes (Y-site compatible)				
For patients with prior pembrolizumab and oxaliplatin reaction, administer oxaliplatin premedications prior to pembrolizumab				
NO ice chips				
<input type="checkbox"/> Other:				
DOCTOR'S SIGNATURE:				SIGNATURE:
				UC:



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GIGAVCOXP

(Page 2 of 2)

DATE:	
** Have Hypersensitivity Reaction Tray & Protocol Available **	
TREATMENT: <input type="checkbox"/> Repeat in three weeks	
pembrolizumab line to be primed with NS; oxaliplatin line to be primed with D5W	
pembrolizumab 2 mg/kg x _____ kg = _____ mg (max. 200 mg) IV in 50 mL NS over 30 minutes using a 0.2 micron in-line filter	
oxaliplatin 130 mg/m ² x BSA = _____ mg <input type="checkbox"/> Dose Modification: _____ mg/m ² x BSA = _____ mg IV in 250 to 500 mL D5W over 2 hours. Flush line with D5W pre and post dose.	
For moderate vascular pain during peripheral administration: 250 mL D5W at maximum rate of 125 mL/h concurrently with oxaliplatin prn OR <input type="checkbox"/> 500 mL D5W at maximum rate of 250 mL/h concurrently with oxaliplatin prn	
capecitabine 1000 mg/m ² or _____ x BSA x (_____ %) = _____ mg PO BID x 14 days (refer to <u>Capecitabine Suggested Tablet Combination Table</u> for dose rounding)	
RETURN APPOINTMENT ORDERS	
<input type="checkbox"/> Return in three weeks for Doctor and Cycle _____ <input type="checkbox"/> Return in six weeks for Doctor and Cycle _____ & _____. Book treatment x 2 cycles <input type="checkbox"/> Last Cycle. Return in _____ week(s)	
CBC & Diff, creatinine, ALT, total bilirubin, sodium, potassium, TSH prior to each cycle If clinically indicated: <input type="checkbox"/> CEA <input type="checkbox"/> CA 19-9 <input type="checkbox"/> ECG <input type="checkbox"/> chest x-ray <input type="checkbox"/> free T3 and free T4 <input type="checkbox"/> lipase <input type="checkbox"/> morning serum cortisol <input type="checkbox"/> random glucose <input type="checkbox"/> alkaline phosphatase <input type="checkbox"/> albumin <input type="checkbox"/> GGT <input type="checkbox"/> creatine kinase <input type="checkbox"/> troponin <input type="checkbox"/> serum ACTH levels <input type="checkbox"/> testosterone <input type="checkbox"/> estradiol <input type="checkbox"/> FSH <input type="checkbox"/> LH <input type="checkbox"/> serum HCG or <input type="checkbox"/> urine HCG – required for woman of childbearing potential <input type="checkbox"/> INR weekly <input type="checkbox"/> INR prior to each cycle <input type="checkbox"/> Weekly nursing assessment <input type="checkbox"/> Other consults: <input type="checkbox"/> See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: